Entering text into the input field will update the search result below

Akebia Therapeutics wins UK approval of vadadustat for CKD anemia

May 22, 2023 9:22 AM ETAkebia Therapeutics, Inc. (AKBA) StockBy: Jonathan Block, SA News Editor
Broken glass Kidney

Hiroshi Watanabe/DigitalVision via Getty Images

  • The UK's Medicines and Healthcare Products Regulatory Agency has approved Akebia Therapeutics' (NASDAQ:AKBA) Vafseo (vadadustat) for symptomatic anemia associated with chronic kidney disease.
  • The approval was supported by data from 7.5K patients.
  • According to the company, vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.
  • Vafseo was approved in the European Union in late April.

More on Akebia

Recommended For You

More Trending News

About AKBA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AKBA--
Akebia Therapeutics, Inc.